Cash-strapped Acer sees menopause drug flunk phase 2 trial

Acer Therapeutics’ ambitions for menopause drug osanetant have hit a roadblock after the candidate failed to reduce hot flashes in a mid-stage trial, missing the primary endpoint. The news comes at a bad time as the biotech hunts for cash to keep operations going.